论文部分内容阅读
目的:研究喉癌组织中高迁移率族蛋白B1(HMGB1)以及基质金属蛋白酶2(MMP2)、基质金属蛋白酶9(MMP9)的含量检测及其与预后情况的相关性。方法:选取在本院接受喉癌手术治疗的120例患者纳入研究,采用免疫组化的方法检测喉癌组织中HMGB1以及MMP2、MMP9的表达情况,并随访患者的复发率和生存率。结果:HMGB1、MMP2、MMP9的阳性率分别为65.83%、69.17%、65.83%,且HMGB1、MMP2、MMP9阳性患者的肿瘤分期高于阴性患者,分化程度低于阴性患者,差异具有统计学意义(P<0.05);;单因素分析显示HMGB1、MMP2、MMP9阳性患者的无瘤生存时间短于阴性患者,五年存活率低于阴性患者,差异具有统计学意义(P<0.05);logistic回归分析显示HMGB1、MMP2、MMP9阳性表达是五年存活的危险因素。结论:HMGB1、MMP2、MMP9的表达情况可作为判断喉癌患者预后情况的可靠指标,四项指标联合检测可对患者的病情进行全面判断,并针对性的制定综合治疗方案。
OBJECTIVE: To study the detection of high mobility group box 1 (HMGB1), matrix metalloproteinase 2 (MMP2) and matrix metalloproteinase 9 (MMP9) in laryngeal carcinoma and its relationship with prognosis. Methods: A total of 120 patients undergoing laryngeal cancer surgery in our hospital were enrolled in the study. The expression of HMGB1, MMP2 and MMP9 in laryngeal carcinoma were detected by immunohistochemistry. The recurrence rate and survival rate of the patients were followed up. Results: The positive rates of HMGB1, MMP2 and MMP9 were 65.83%, 69.17% and 65.83%, respectively. The staging of HMGB1, MMP2 and MMP9 positive patients was higher than that of negative patients, the differentiation degree was lower than that of negative patients P <0.05). The univariate analysis showed that the survival time of HMGB1, MMP2 and MMP9 positive patients was shorter than that of negative patients, and the five-year survival rate was lower than that of negative patients (P <0.05). Logistic regression analysis It showed that the positive expression of HMGB1, MMP2 and MMP9 were the risk factors of five-year survival. Conclusion: The expression of HMGB1, MMP2 and MMP9 can be used as a reliable indicator to evaluate the prognosis of patients with laryngeal cancer. The combined detection of four indexes can make a comprehensive judgment of the patients’ condition and make a comprehensive treatment plan.